Global Biological Therapy Market – Industry Trends and Forecast to 2029

Biological Therapy Market Analysis and Size

The global biological therapy market  is expected to witness significant growth during the forecast period. The worldwide biological therapy market is projected to rise critically in the upcoming few years. This therapy fundamentally uses the body's system either straightforwardly or by implication to battle cancer. Numerous specialists in the cancer biological therapy market are focusing on utilizing nanotechnology to offer development therapy to patients. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global biological therapy market  in the forecast period 2022-2029. The expected CAGR of global biological therapy market  is tend to be around 9.32% in the mentioned forecast period. The market was valued at USD 350.21 billion in 2021, and it would grow upto USD 714.37 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Biological therapy is cancer treatment that uses the body's immune system to fight against cancerous cells without affecting the healthy cells. The biological drug therapy such as monoclonal antibodies exerts their action by either hindering the cancer growth or rise cell death. The different types of biological therapies are interferons, monoclonal antibodies, interleukins, and vaccines. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Biological Therapy Market Scope and Segmentation

Global Biological Therapy Market Dynamics

Drivers

• Increase in Cancer Cases

The rise in cancer cases globally boosts the global cancer biological therapy market in the forecast period As per the reports of the American Cancer Society Statistics in 2016, majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with an estimated global death rate being 30,000 per year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women causing 1.59 million deaths in 2012. This boost the market growth.

• Advancements in Biomedical Science

Biological drugs result from innovative research and allow for the most recent scientific breakthroughs, which can lead to novel medicines that offer patients several new treatment options. Additionally, better knowledge on the genetic and molecular level has paved the way for several advanced treatments. For instance, recombinant proteins help the immune system identify and bind foreign molecules. Biologics are estimated to grow promptly in the next years due to the high productivity of small molecule therapeutics. Major market players in the pharmaceutical industry are continuously focusing on developing innovative drugs to keep up with the competition.

Opportunities

• Rising Cases of Chronic Diseases

Continuous advances in biotechnology and biomedical science techniques have significantly enhanced the process of developing biologics for treating various chronic illnesses. Products range from simple monoclonal antibodies to targeted pharmaceuticals such as antibody-drug conjugates, radio immunotherapies, and bispecific antibodies that can target multiple locations simultaneously. Thus, all these factors create many opportunities for market growth as the need for biological therapy increases.

• Growing Relevance of Biological Therapy with Other Diseases

Biological treatments are becoming more important in a rising variety of illness categories. These firms will be looking for ways to increase their disease-area leadership by investing more in biologic medicines and biotech capabilities. For instance, AstraZeneca, one of the top leading firms in the respiratory sector is all set to join the respiratory biologics market with its new drug, benralizumab. This is anticipated to provide new hope to cancer patients.

Restraints/Challenges

• Lack of Authorized Support

Lack of support from recognized authorizations could limit the growth of the global biological therapy market over a forecast period. Several medical insurance companies in numerous developing countries such as India do not cover biological therapy and there is not much government support. This hampers the market growth.

• Increasing Cost Of Treatments

The huge expenditure required for the treatment methods surely hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.

This global biological therapy market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global biological therapy market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Biological Therapy Market

The COVID-19 pandemic has had a significant detrimental influence on the global biological therapy market. The supply chain of biologics was disturbed because of the COVID-19 outbreak and lockdown. Hospitals and clinics are predominantly reserved for severe and critical COVID-19 patients. Researchers faced hurdles associated with different other diseases. The demand for several vaccinations and other preventative majors increased dramatically as a result of COVID-19. Since these vaccines were dominating the market, the impact of COVID-19 on the biologics market was minimal. However, in the post-pandemic era, the market showed a high rise and is expected to rise high in the upcoming years.

Recent Developments

• In Feb 2021, GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration to jointly develop next-generation mRNA vaccines for COVID-19 with the utmost potential and aim to develop and address several evolving variants in a single vaccine.
• In April 2021, BMS announced its plans to build a new manufacturing site for the cell therapy division in the Netherlands.

Global Biological Therapy Market Scope

The global biological therapy market  is segmented on the basis of type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Monoclonal Antibodies
•  Naked monoclonal antibodies
• Conjugated monoclonal antibodies
• Bispecific monoclonal antibodies
• Vaccines
• Preventive vaccines
• Therapeutic vaccines
• Cancer Growth Blockers
• Tyrosine kinase inhibitors
• Proteasome inhibitors
• mTOR inhibitors
• Cytokine
• Interferons
• Interleukins
• Others

Route of Administration

• Intravenous
• Subcutaneous
• Intramuscular
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Cancer Biological Therapy Market Regional Analysis/Insights

The global biological therapy market  is analysed and market size insights and trends are provided by type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global biological therapy market  are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to have the highest market growth due to the increase prevalence of cancer, high demand of biological therapies and advanced healthcare facilities.

North America dominates the market due to the increase awareness about the diseases and rapidly disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Cancer Biological Therapy Market Share Analysis

The global biological therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global biological therapy market 

Key players operating in the global biological therapy market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Endo Pharmaceuticals plc (Ireland)
• Zydus Group (India)
• Bausch Health Companies Inc. (Canada)

SKU-54324